Abstract | OBJECTIVE: METHODS: We performed a retrospective analysis of eyes that received intravitreous bevacizumab, 1.25 mg, for subfoveal non-AMD CNV at a referral-based retinal practice. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. The main outcome measure was visual acuity (VA). RESULTS: The study included 39 eyes of 36 patients with subfoveal CNV secondary to multifocal choroiditis (n = 12), angioid streaks (n = 11), myopic degeneration (n = 10), idiopathic disease (n = 4), or other disease (n = 2). The median baseline VA was 20/60 (logMAR, 0.48). The mean follow-up was 58.8 weeks, and the mean number of injections per eye was 3.4. After 3-month follow-up, the median VA was 20/30 (logMAR, 0.18) (P = .004 vs baseline). At last follow-up, the median VA was 20/40 (logMAR, 0.30). This remained an improvement compared with baseline (P < .02) but was worse than 3-month follow-up (P < .03). There was no correlation between underlying diagnosis and VA change during follow-up. CONCLUSION: Subfoveal CNV secondary to non-AMD causes treated with intravitreous bevacizumab responded favorably and similarly, despite varying underlying etiologies.
|
Authors | Louis K Chang, Richard F Spaide, Claudia Brue, K Bailey Freund, James M Klancnik Jr, Jason S Slakter |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 126
Issue 7
Pg. 941-5
(Jul 2008)
ISSN: 1538-3601 [Electronic] United States |
PMID | 18625940
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Triamcinolone Acetonide
|
Topics |
- Adult
- Angiogenesis Inhibitors
(therapeutic use)
- Angioid Streaks
(complications)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroidal Neovascularization
(drug therapy, etiology)
- Choroiditis
(complications)
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Fovea Centralis
- Humans
- Injections
- Macular Degeneration
(complications)
- Male
- Middle Aged
- Myopia, Degenerative
(complications)
- Photochemotherapy
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Triamcinolone Acetonide
(therapeutic use)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
- Vitreous Body
|